South Korean Fashion Labels Unite to Combat Counterfeit Products 
Rivian's Earth Day Special: $5,000 Off for Trading Gas Cars for Electric 
Tevfik Arif shares his take on the post-COVID-19 real estate market in New York City 
ADM’s Suspended CFO to Resign After Accounting Probe 
Disney Entertainment CTO to Step Down and Move to PENN Entertainment 
Coca-Cola, Microsoft Forge $1.1B Alliance for Cloud and AI Innovation 
Kroger and Albertsons Extend Store Sale to C&S by 166 Stores in Push for Merger Approval 
Apple Buys French AI Firm to Boost Privacy-Focused On-Device Processing 
Apple Adds Eight Chinese Companies to Its Supply Chain After Axing Four 
Airbus Recruits Former JetBlue CEO Robin Hayes to Lead North American Operations 
The language of insolvency: why getting it wrong can harm struggling firms 
Adidas Unveils Groundbreaking Wheelchair Basketball Uniforms in Collaboration with Adaptive Sports Northwest 
Lotte Department Store Launches AI Translation Service for Foreign Customers 
Amazon to Introduce Air Delivery Service in Arizona via Drone 
BYD Unwraps New Electric Pickup Truck It Named BYD Shark 
A Blend of Tradition and Technology: Finnish Roastery Launches AI-Developed Coffee Blend 
Lotte Starts Online Sales of Premium Bacha Coffee Line 
WALTHAM, Mass., Nov. 22, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Citi 2017 Global Healthcare Conference at the Lotte New York Palace in New York, New York on Thursday, December 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will participate in an analyst-led moderated Q&A from 1:25 to 2:05 PM ET and in meetings with investors.
- The Guggenheim Securities 5th Annual Boston Healthcare Conference at the Intercontinental in Boston, Massachusetts on Wednesday, December 13. Tim Pearson, Executive Vice President and CFO of TESARO, will participate in meetings with investors.
A live webcast of the analyst-led Q&A discussion at the Citi conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conference.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
Vice President, Corporate Communications & Investor Relations
1.781.325.1116
[email protected]
